Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

Stock Information for Relmada Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Relmada Therapeutics Inc.

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.